NASDAQ$PTGX
Protagonist Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Protagonist Therapeutics reported progress in its clinical programs, including proof-of-concept data for rusfertide in hereditary hemochromatosis and the resumption of rusfertide clinical studies following the resolution of an FDA clinical hold. PN-235 is advancing into a Phase 2 study in psoriasis in early 2022.
- Resumed Phase 2 study of rusfertide in polycythemia vera after FDA clinical hold removal.
- Presented positive proof-of-concept data for rusfertide in hereditary hemochromatosis at The Liver Meeting®.
- PN-235 is moving into a psoriasis indication, with Phase 2 study initiation planned for early 2022.
- PN-943 Phase 2 study for ulcerative colitis is underway with data readout expected in Q2 2022.
Headline financials
Revenue & EPS history
Protagonist · Revenue · Quarterly
$10.3M
Forward guidance
Protagonist Therapeutics is advancing its clinical programs and anticipates key milestones in the near term.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+3.2%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+8.3%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+75.1%
Q1 2020
Best reaction
-21.2%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -0.2% | +3.3% | |
| Q4 2025 | -0.3% | +7.8% | +13.3% | |
| Q3 2025 | -0.2% | +6.4% | +12.4% | |
| Q1 2025 | +2.4% | +3.2% | +22.9% | |
| Q4 2024 | -7.1% | -6.2% | +35.6% | |
| Q3 2024 | -2.9% | -9.3% | -11.6% | |
| Q2 2024 | +0.0% | +8.2% | +17.4% | |
| Q1 2024 | +4.0% | +8.3% | +30.5% | |
| Q4 2023 | +3.0% | +8.9% | -2.0% | |
| Q3 2023 | +10.2% | +9.0% | +22.8% | |
| Q2 2023 | +3.3% | -2.0% | +5.2% | |
| Q1 2023 | +1.5% | +3.3% | +15.3% | |
| Q4 2022 | -8.4% | -9.9% | -25.9% | |
| Q3 2022 | -0.5% | +9.4% | +0.4% | |
| Q2 2022 | +2.2% | -1.6% | -21.1% | |
| Q1 2022 | -0.3% | -10.3% | -6.4% | |
| Q4 2021 | +7.2% | -0.7% | -2.3% | |
| Q3 2021 | +5.0% | +7.4% | +0.1% | |
| Q2 2021 | -2.2% | -0.4% | -0.8% | |
| Q1 2021 | -0.4% | -0.1% | +19.3% | |
| Q4 2020 | +3.5% | +2.8% | -11.4% | |
| Q3 2020 | +14.2% | +6.6% | +11.0% | |
| Q2 2020 | +8.3% | +2.3% | +23.8% | |
| Q1 2020 | +75.1% | +97.4% | +98.0% | |
| Q4 2019 | -4.8% | +5.1% | -7.6% | |
| Q3 2019 | -19.3% | -14.2% | -37.5% | |
| Q2 2019 | +0.8% | -2.9% | +60.6% | |
| Q1 2019 | +20.8% | +16.3% | +31.4% | |
| Q4 2018 | +0.1% | +22.3% | +22.2% | |
| Q3 2018 | +14.1% | +22.3% | -14.6% | |
| Q2 2018 | -1.8% | -6.4% | -18.1% | |
| Q1 2018 | -21.2% | -22.4% | -13.5% | |
| Q4 2017 | -2.0% | +1.4% | -57.5% | |
| Q3 2017 | +8.9% | +16.2% | +25.2% | |
| Q2 2017 | -7.7% | -4.4% | +33.6% | |
| Q1 2017 | +10.5% | +14.3% | +21.1% | |
| Q4 2016 | -0.6% | +0.4% | -16.8% | |
| Q3 2016 | -1.6% | +3.4% | -16.5% | |
| Q2 2016 | +9.4% | +19.1% | +63.8% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro